Dzięcioł M. Mordak R., Dejneka G.J., Twardoń J., Mrowiec J., Dzimira S. and Stefaniak T.
Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Wroclaw,
Introduction: In recent years the stem cells have been used more and more frequent in human and also in veterinary medicine. As a relatively new branch of science and medicine, an extraordinary vigilance must be maintained in introducing it as a routine procedures. In this study the safety of intramammary administration of the homogenate of the antlerogenic stem cells (MIC -1) in dairy cows during lactation was evaluated.
Material and Methods: During experiment 10 Holstein Friesians (HF) cows has been used. The animals had 4-6 years old, were kept in the same conditions and during the whole experiment had the same feeding protocol. During the preliminary trial the general health status as well as health status of the udder were closely examined. There was no general or local, clinically manifested signs of illness in none of animals. During the first part of experiment, all animals received on three consecutive days 5 ml of placebo (aqua pro injectione) administrated into the each quarter of mammary gland through the teat canal. From the first day of the placebo administration and the next seven days, a detailed analysis of the status of the animal and especially mammary gland was monitored. For this purpose throughout the duration of the experiment, every day in addition to the routine clinical examination, qualitative and quantitative analysis of the mammary secretion (milk cytology) was performed (for seven days for each part of experiment). Moreover, morphological analysis of the blood collected at the beginning and at the end of trials has been done and the evaluation of the level of acute-phase protein in blood (haptoglobin /Hp/) and in milk (serum amyloid A /SAA/) was performed. Those parameters were controlled at the begging of the trial (before placebo or homogenate administration) and after three, four and seven days post treatment.
In the second part of experiment the same amount of solution containing homogenate of MIC–1 cells with the concentration of 2mln/ml with the aqua pro injectione as a diluent and according the same protocol were administrated intramammary. The same analysis dedicated to the evaluation of the general health status of cows and the condition of the udders, were performed according to the mentioned above protocol.
Results: In all cases the signs of transient, moderate irritation of the mammary tissue after intramammary infusion has been observed. The increased somatic cell count was noted in all animals from both groups, but there were no significant differences between types of cells observed after placebo and homogenate infusion. The behavior of the acute-phase protein in milk (SAA) was similar in both groups and presented immediate increase at a comparable level after teat infusion. There was correlation between the behaviors of acute phases proteins in blood and in milk, but the decrease of this factors in milk occurred faster. No significant changes in blood morphological parameters was observed. This reaction was similar in both of experimental groups.
Conclusion: The analysis of the obtained results indicates the safety of use of the homogenate of antlerogenic stem cells (MIC -1) in dairy cows during lactation. The further studies are indicated to determine whether this product could be somehow useful in the therapy of the mastitis or in the treatment of the teat injuries in cows.
 Characteristics of antlerogenic stem cells and their potential application. Cegielski et al. Tissue Engineering. Edited by Daniel
Eberli MD PhD ISBN 978-953-307-079-7, 2010.
 Concentrations of serum amyloid-A (SAA) and haptoglobin (HP) as parameters of inflammatory diseases in cattle. Alsemgeest SP, Kalsbeek HC, Wensing T, Koeman JP, van Ederen AM, Gruys E.Vet Q. 1994 Mar; 16(1):21-3.
"Project NR: UOD-DEM-1-351/001 financed by National Centre for Research and Development and by European Regional Development Fund under the Operational Programme Innovative Economy”